MedTrace Logo

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

NCT05764941 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-03-27

No results posted yet for this study

Summary

This is a real world study to evaluate the efficacy and safety of inetetamb combined with pyrotinib and vinorelbine as first-line to third-line treatment after trastuzumab progression in HER2-positive metastatic breast cancer.

Conditions

  • Breast Neoplasms

Interventions

DRUG

Inetetamab

8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.

DRUG

Pyrotinib

400mg, oral, every day.

DRUG

Vinorelbine

25 mg/m2, D1, D8, every 3 weeks for one cycle.

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2024-03-01
Completion
2024-03-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05764941 on ClinicalTrials.gov